{"id":"https://openalex.org/W196332875","doi":"https://doi.org/10.1159/000063644","title":"Treatment Approaches to Major Depressive Disorder Relapse","display_name":"Treatment Approaches to Major Depressive Disorder Relapse","alternate_titles":[],"publication_year":2002,"publication_date":"2002-07-01","ids":{"openalex":"https://openalex.org/W196332875","doi":"https://doi.org/10.1159/000063644","mag":"196332875","pmid":"https://pubmed.ncbi.nlm.nih.gov/12097784"},"language":"en","primary_location":{"id":"doi:10.1159/000063644","doi":"https://doi.org/10.1159/000063644","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000063644","pdf_url":null,"source":{"id":"https://openalex.org/S184803288","display_name":"Psychotherapy and Psychosomatics","issn_l":"0033-3190","issn":["0033-3190","1423-0348"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychotherapy and Psychosomatics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W196332875"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5084024326","display_name":"Maurizio Fava","orcid":"https://orcid.org/0000-0002-4635-0458","observed_orcids":["https://orcid.org/0000-0002-4635-0458"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maurizio Fava","raw_affiliation_strings":["Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA. mfava@partners.org","Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass., and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass 02114, USA. mfava@partners.org","institution_ids":["https://openalex.org/I4210087915"]},{"raw_affiliation_string":"Depression Clinical and Research Program, Massachusetts General Hospital, Boston, Mass., and","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080344209","display_name":"Mark E. Schmidt","orcid":"https://orcid.org/0000-0003-3417-8977","observed_orcids":["https://orcid.org/0000-0003-3417-8977"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark E. Schmidt","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, Ind., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, Ind., USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100634784","display_name":"Shuyu Zhang","orcid":"https://orcid.org/0000-0003-1419-3635","observed_orcids":["https://orcid.org/0000-0003-1419-3635"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Shuyu Zhang","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, Ind., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, Ind., USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000488904","display_name":"Jill S Gonzales","orcid":"https://orcid.org/0000-0002-0526-4166","observed_orcids":["https://orcid.org/0000-0002-0526-4166"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jill Gonzales","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, Ind., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, Ind., USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034057490","display_name":"Nancy J. Raute","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nancy J. Raute","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, Ind., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, Ind., USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103419905","display_name":"Rajinder Judge","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rajinder Judge","raw_affiliation_strings":["Lilly Research Laboratories, Indianapolis, Ind., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly Research Laboratories, Indianapolis, Ind., USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.8227,"has_fulltext":false,"cited_by_count":46,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.89822083,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":95},"biblio":{"volume":"71","issue":"4","first_page":"195","last_page":"199"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10853","display_name":"Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/3205","display_name":"Experimental and Cognitive Psychology"},"field":{"id":"https://openalex.org/fields/32","display_name":"Psychology"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9919999837875366},{"id":"https://openalex.org/keywords/relapse","display_name":"relapse","score":0.753000020980835},{"id":"https://openalex.org/keywords/fluoxetine","display_name":"fluoxetine","score":0.9629999995231628},{"id":"https://openalex.org/keywords/rechallenge","display_name":"drug rechallenge","score":0.796999990940094},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.578000009059906},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.6899999976158142},{"id":"https://openalex.org/keywords/antidepressant-efficacy","display_name":"antidepressant efficacy","score":0.5550000071525574},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5260000228881836},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.7300000190734863},{"id":"https://openalex.org/keywords/ham-d-17","display_name":"HAM-D-17","score":0.5210000276565552},{"id":"https://openalex.org/keywords/relapse-prevention","display_name":"relapse prevention","score":0.40799999237060547}],"concepts":[{"id":"https://openalex.org/C2776134451","wikidata":"https://www.wikidata.org/wiki/Q422244","display_name":"Fluoxetine","level":4,"score":0.9386748671531677},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.8243093490600586},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.6734442114830017},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5629990696907043},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4906712770462036},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.4905833303928375},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46102175116539},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.43188416957855225},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.4254765510559082},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.41121917963027954},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003865","descriptor_name":"Major Depressive Disorder","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005473","descriptor_name":"Fluoxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1159/000063644","doi":"https://doi.org/10.1159/000063644","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000063644","pdf_url":null,"source":{"id":"https://openalex.org/S184803288","display_name":"Psychotherapy and Psychosomatics","issn_l":"0033-3190","issn":["0033-3190","1423-0348"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","erih-plus","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychotherapy and Psychosomatics","raw_type":"journal-article"},{"id":"pmid:12097784","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12097784","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Psychotherapy and psychosomatics","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":4,"referenced_works":["https://openalex.org/W1972494288","https://openalex.org/W2046202057","https://openalex.org/W2166904537","https://openalex.org/W4248498496"],"related_works":["https://openalex.org/W1499070344","https://openalex.org/W2346169180","https://openalex.org/W1811060604","https://openalex.org/W2091022482","https://openalex.org/W969979281","https://openalex.org/W2180487108","https://openalex.org/W2116416511","https://openalex.org/W2103553382","https://openalex.org/W1963620554","https://openalex.org/W2165564184"],"abstract_inverted_index":{"BACKGROUND:":[0],"Anecdotal":[1],"reports":[2],"concerning":[3],"mood":[4],"disorder":[5,66],"patients":[6,12,40,146,158,172,250,271,308,328,390],"suggest":[7],"restarting":[8],"drug":[9],"treatment":[10,38,134,150,203,387],"in":[11,39,91,389],"who":[13,60,198,272,391],"prematurely":[14,365],"discontinue":[15],"it":[16],"may":[17],"be":[18],"associated":[19],"with":[20,68,83,151,204],"a":[21,47,92,174,186,342,385,395],"diminished":[22,368],"chance":[23],"of":[24,32,36,51,56,117,131,191,212,216,226,238,262,282,307,321,346,351,362,380],"response":[25,33,333],"upon":[26,274,337],"rechallenge.":[27],"We":[28],"evaluated":[29],"the":[30,62,124,137,189,192,196,349,357,360,381],"likelihood":[31],"to":[34,44,102,167,182,230,252,265,276,280,293,302,334,339,348],"reinitiation":[35,281,320,350,379],"fluoxetine":[37,87,106,112,152,160,283,352],"relapsing":[41,122],"after":[42,319,330,393],"switching":[43,275,338],"placebo":[45,148,205,277,340],"during":[46,123,135,257],"long-term":[48],"efficacy":[49,361],"study":[50,138,325],"two":[52],"different":[53],"dosing":[54],"regimens":[55],"fluoxetine.":[57],"METHOD:":[58],"Patients":[59,121],"met":[61],"DSM-IV":[63],"major":[64],"depressive":[65],"criteria":[67],"modified":[69,217,287],"HAMD17":[70,218,288],"scores":[71,77],">":[72,78],"or":[73,79,108,222,313],"=18":[74],"and":[75,170,219,224,243,297],"CGI-Severity":[76,220],"=4":[80],"were":[81,100,127],"treated":[82],"open-label":[84],"20":[85,104,153,161,292],"mg/day":[86,162],"for":[88,114,195,300],"13":[89],"weeks":[90,116,130],"multicenter":[93],"US":[94],"study.":[95],"Responders":[96],"(n":[97],"=":[98],"501)":[99],"randomized":[101],"placebo,":[103,253],"mg":[105,110,184],"daily,":[107],"90":[109,183],"enteric-coated":[111],"weekly":[113,176],"25":[115,129],"double-blind":[118,132,267],"continuation":[119,125,202,258],"treatment.":[120,259,269,353],"phase":[126,194],"offered":[128],"rescue":[133,193,268],"which":[136],"medication":[139],"dose":[140,165,177,180],"was":[141,298],"increased":[142,166,181],"as":[143,384],"follows:":[144],"(1)":[145],"on":[147,159,173,201],"had":[149,163,178],"mg/":[154],"day":[155],"reinitiated;":[156],"(2)":[157],"their":[164,179],"40":[168],"mg/day,":[169],"(3)":[171],"90-mg":[175],"twice":[185],"week.":[187],"Only":[188],"results":[190,355],"group":[197],"relapsed":[199,256,273,318,392],"while":[200],"are":[206],"reported":[207],"here.":[208],"Analyses":[209],"included":[210,236],"percentage":[211],"responders":[213],"(50%":[214],"reduction":[215],"<":[221],"=2)":[223],"assessments":[225],"change":[227],"from":[228,291],"baseline":[229],"endpoint":[231],"(HAMD,":[232],"CGI-Severity).":[233],"Safety":[234],"measures":[235],"assessment":[237],"vital":[239],"signs,":[240],"laboratory":[241],"measures,":[242],"treatment-emergent":[244],"adverse":[245],"events.":[246],"RESULTS:":[247],"Of":[248],"122":[249],"assigned":[251],"57":[254],"(47%)":[255],"Fifty-five":[260],"(96%)":[261],"these":[263],"elected":[264],"enter":[266],"Overall,":[270],"responded":[278,315],"well":[279],"(62%).":[284],"The":[285],"mean":[286],"score":[289],"decreased":[290],"less":[294],"than":[295],"9":[296],"maintained":[299],"up":[301],"6":[303],"months.":[304],"Thirty-eight":[305],"percent":[306],"either":[309],"did":[310],"not":[311],"respond":[312],"initially":[314],"but":[316],"again":[317],"medication.":[322],"CONCLUSION:":[323],"This":[324],"suggests":[326],"that":[327,359],"who,":[329],"an":[331,363,371],"initial":[332],"fluoxetine,":[335],"relapse":[336],"have":[341],"relatively":[343],"high":[344],"probability":[345],"responding":[347],"These":[354],"challenge":[356],"view":[358],"agent":[364,372],"discontinued":[366],"is":[367,373],"when":[369],"such":[370],"restarted.":[374],"They":[375],"also":[376],"generally":[377],"support":[378],"same":[382],"antidepressant":[383],"'first-line'":[386],"strategy":[388],"stopping":[394],"previously":[396],"effective":[397],"antidepressant.":[398]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W196332875","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-18T13:11:19.462570","created_date":"2016-06-24T00:00:00"}
